跳至主要内容
临床试验/EUCTR2012-002096-34-NL
EUCTR2012-002096-34-NL进行中(未招募)不适用

Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur® - AER-2012

Crucell Holland B.V.0 个研究点开始时间: 2012年7月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age between 18 and 65 year
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • A know or suspected allergy towards one of the components of the vaccine, i.e. chicken protein, polygeline, neomycin, chlorotetracyclin and amfotericine B.
  • History of serious allergic reactions
  • Use of medication to suppress immune response
  • A chronic disease that affects the immune system, systemic diseases such as SLE, ANCA associated vasculitis
  • Pregnancy or actual child wish (upon inquiry at the time of screening)

研究者

相似试验